Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dole

Showing results (121-130 of 166) with videos related to

Pageof 17
Sort By:
Circulation|June 19, 2008
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humansNaomi D L Fisher, A H Jan Danser, J Nussberger, et al.
Obstetrics and Gynecology|June 1, 1996
Characteristics of menstruation in women infected with human immunodeficiency virusT V Ellerbrock, T C Wright, T J Bush, et al.
Current Medical Research and Opinion|April 15, 2009
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetesYan-Ling He, Ron Sabo, Franck Picard, et al.
Cardiovascular Therapeutics|November 28, 2008
Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjectsSujata Vaidyanathan, Michael Bartlett, Hans Armin Dieterich, et al.
Clinical Pharmacokinetics|July 28, 2007
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairmentSujata Vaidyanathan, Hilde Bigler, ChingMing Yeh, et al.
Current Medical Research and Opinion|September 13, 2008
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjectsSujata Vaidyanathan, Mojdeh Maboudian, Vance Warren, et al.
Journal of Clinical Pharmacology|March 29, 2007
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjectsSujata Vaidyanathan, Christine Reynolds, Ching-Ming Yeh, et al.
British Journal of Clinical Pharmacology|July 21, 2010
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetesYan-Ling He, Jessica Valencia, Yiming Zhang, et al.
Cardiovascular Research|September 1, 1984
Diastolic coronary artery pressure-flow velocity relationships in conscious manW P Dole, K L Richards, C J Hartley, et al.
Current Medical Research and Opinion|February 1, 2008
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjectsSurya Ayalasomayajula, Stéphanie Tchaloyan, Ching-Ming Yeh, et al.
Pageof 17

Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
Circulation|June 19, 2008
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humansNaomi D L Fisher, A H Jan Danser, J Nussberger, et al.
Obstetrics and Gynecology|June 1, 1996
Characteristics of menstruation in women infected with human immunodeficiency virusT V Ellerbrock, T C Wright, T J Bush, et al.
Current Medical Research and Opinion|April 15, 2009
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetesYan-Ling He, Ron Sabo, Franck Picard, et al.
Cardiovascular Therapeutics|November 28, 2008
Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjectsSujata Vaidyanathan, Michael Bartlett, Hans Armin Dieterich, et al.
Clinical Pharmacokinetics|July 28, 2007
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairmentSujata Vaidyanathan, Hilde Bigler, ChingMing Yeh, et al.
Current Medical Research and Opinion|September 13, 2008
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjectsSujata Vaidyanathan, Mojdeh Maboudian, Vance Warren, et al.
Journal of Clinical Pharmacology|March 29, 2007
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjectsSujata Vaidyanathan, Christine Reynolds, Ching-Ming Yeh, et al.
British Journal of Clinical Pharmacology|July 21, 2010
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetesYan-Ling He, Jessica Valencia, Yiming Zhang, et al.
Cardiovascular Research|September 1, 1984
Diastolic coronary artery pressure-flow velocity relationships in conscious manW P Dole, K L Richards, C J Hartley, et al.
Current Medical Research and Opinion|February 1, 2008
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjectsSurya Ayalasomayajula, Stéphanie Tchaloyan, Ching-Ming Yeh, et al.
Pageof 17